| Biological Information | |
|---|---|
| Background Information: | CDDO Methyl Ester (bardoxolone methyl) is a semi-synthetic triterpenoid developed from the oleanolic acid scaffold that induces apoptosis and differentiation in tumor cells. Agonist of the KEAP1-Nrf2 pathway, thus inducing expression of antioxidant proteins and protection against oxidative damage from injury and inflammation. Also an antagonist of the NF-kB pro-inflammatory transcription factor and PPARG. Underwent clinical trials for type 2 diabetes treatment, due to its potent antidiabetic activity, but was confirmed to enhance cardiac disease during a phase 2 trial in October 2012. Provided as 5 mg of dry powder. |
| Target Name: | Bardoxolone Methyl |
| Usage | |
| Product Type: | Control Ligands & Inhibitors |
| Application: | Drug Discovery & Development |
| Storage Conditions: | Store at 2-8°C. Please avoid multiple freeze/thaw cycles. |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
| Additional Information | |
| Brand: | DiscoverX |
CDDO Methyl Ester
CDDO Methyl Ester is an agonist for the KEAP1-Nrf2 pathway. This product is provided as 5 mg of dry powder.
Datasheets
92-1147 Datasheet
View Document